Register for free to
view the full innovation profile.
A peptoid-peptide hybrid, NMEG-aCGRP, and its use in cardiovascular diseases Inventor: Shannon Servoss, Jay Potts, Ambrish Kumar, Donald Dipette
About
In an effort to save the lives of millions of people suffering from various cardiovascular diseases (CVD), researchers at the University of Arkansas have developed a novel vasodilator called 2-methoxyethyl glycine (NMEG)-calcitonin gene-related peptide (aCGRP) that could help treat conditions like heart attack, heart failure, high blood pressure, hypertension, and other cardiovascular diseases. The advancement of this technology could improve the traditional methods used to treat heart failure. NMEG-aCGRP promises to be one of the most robust vasodilators with enhanced stability and performance to treat CVD. It eliminates the drawback posed by the short half-life of aCGRP in the human serum. NMEG-aCGRP has proven to be more stable with experiments done on mice models and has been demonstrated to exhibit extended resistance to degradation while retaining identical biological activity of the original molecule. NMEG-aCGRP capitalizes on the crucial need to develop new therapies to treat longstanding CVD.
Key Benefits
This peptoid-peptide hybrid retains the activity of the original peptide with increased stability. Synthesis of the peptoid is simple and cost effective. This peptoid has shown to be non-toxic when tested on two cardiac myocyte cell lines.
Applications
Treatment of hypertension, heart failure, and other cardiovascular diseases.